Extended Data Fig. 2: Progression-free Survival by PD-L1 expression subgroups. | Nature Medicine

Extended Data Fig. 2: Progression-free Survival by PD-L1 expression subgroups.

From: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Extended Data Fig. 2

Kaplan-Meier estimates of PFS as assessed by a blinded independent review committee according to RECIST v1.1 are shown to compare the toripalimab plus chemotherapy arm with the placebo plus chemotherapy arm in PD-L1 + and PD-L1- subgroups. PD-L1 positive status was defined as the presence of membrane staining of any intensity in ≥1% of tumor cells or immune cells by JS311 IHC staining. Censored patients are marked with “┃” in the graph. Numbers of patients at risk at indicated time points are shown below the x-axis. Number of events and median PFS rates are shown to the right of Kaplan-Meier curves.

Source data

Back to article page